Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma
Frontiers in Oncology · 07.07.2026 · 16
DOI: 10.3389/fonc.2026.1859319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 07.07.2026. Verfasst von Yongliang Niu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant chemoimmunotherapy is standard for locally advanced lung squamous cell carcinoma (SCC), but reliable predictive biomarkers for pathological response are lacking. Ki-67 has shown promise in advanced disease, yet its role in the neoadjuvant setting remains undefined.
Methods
We retrospectively analyzed 137 patients with stage IIIA–IIIB lung SCC who received neoadjuvant PD-1 inhibitors plus platinum−based chemotherapy followed by surgery (2022–2025). Major pathological response (MPR) and pathological complete response (pCR) were assessed per IASLC criteria and combined as MPR/pCR. Ki-67 expression was measured by immunohistochemistry (clone UMAB107). ROC curve, univariate and multivariate logistic regression were used to evaluate predictive performance.
Results
MPR/pCR was achieved in 77/137 patients (56.2%). The optimal Ki-67 cutoff was 55% (AUC = 0.785, 95%CI: 0.707–0.862, P<0.001). High Ki-67 (≥55%) was associated with a significantly higher MPR/pCR rate than low Ki-67 (69.6% vs. 27.9%, P<0.001). In multivariate analysis, Ki-67 expression (adjusted OR per 1% increase =1.069, 95%CI: 1.043–1.096, P<0.001) and smoking status (adjusted OR = 5.405, 95%CI: 1.515–19.280, P = 0.009) were independent predictors of MPR/pCR. PD-L1 expression showed no significant association (P = 0.607).
Conclusions
Pretreatment Ki-67 expression (optimal cutoff 55% in this cohort) is a robust independent predictor of pathological response to neoadjuvant chemoimmunotherapy in locally advanced lung SCC. Smoking status is also an independent predictor. Ki-67 assessment may help identify patients likely to benefit from neoadjuvant therapy, but prospective multi−center validation is required before routine clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Respiratory and Critical Care Medicine, No.2 People's Hospital of Fuyang City, Fuyang Infectious Disease Clinical College of Anhui Medical University, Fuyang, China.
- Department of Pathology, Linquan County People's Hospital, Fuyang, Anhui, China.
- Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Oncology, Anhui Chest Hospital, Hefei, China.
Zitieren
APA
Niu, Y., Li, J., Ding, B., Yang, H., Zhao, H., & Wang, D. (2026). Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1859319
Vancouver
Niu Y, Li J, Ding B, Yang H, Zhao H, Wang D. Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1859319
BibTeX
@article{Niu2026,
author = {Niu, Yongliang and Li, Junguo and Ding, Bowen and Yang, Haitang and Zhao, Hui and Wang, Diming},
title = {Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1859319}
}
EUVIMED